AI assistant
Sending…
RESMED INC — Director's Dealing 2019
Jan 16, 2019
30071_dirs_2019-01-16_2fc5bd33-2d5b-449f-91b8-bdd29b762cc2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RESMED INC (RMD)
CIK: 0000943819
Period of Report: 2019-01-14
Reporting Person: Farrell Michael J. (Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-01-14 | ResMed Common Stock | M | 6651 | $43.63 | Acquired | 292933 | Direct |
| 2019-01-14 | ResMed Common Stock | S | 6651 | $113.75 | Disposed | 286282 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-01-14 | ResMed Common Stock Options | $43.63 | M | 6651 | Disposed | 2020-03-01 | ResMed Commmon Stock (6651) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| ResMed Common Stock | 10340 | Indirect |
Footnotes
F1: The transaction was conducted under a Rule 10b5-1 plan.
F2: This transaction was executed in multiple trades at prices ranging from $113.38 to $114.07. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 annually.
More from RESMED INC
Regulatory Filings
2026
May 26
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Mar 3
Director's Dealing
2026
Feb 10
Regulatory Filings
2026
Feb 9
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 6
Director's Dealing
2026
Feb 3
Interim / Quarterly Report
2026
Jan 30
Regulatory Filings
2026
Jan 29